TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Talking About Traumatic Events - A Randomized Controlled Dissemination Study of the Treatment of PTSD in an African Refugee Settlement
Brief Summary: The study is a pragmatic trial to study the efficacy of two active methods of psychotherapy for the treatment of posttraumatic stress disorder in a refugee camp in Africa. Treatment was administered by lay counsellors.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Narrative Exposure Therapy | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Trauma Counselling | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Narrative Exposure Therapy; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Trauma Counselling; Assigned to Arm(s): 2
B: Arm Label: Psychosocial counseling; Type: N/A; Interventions: N/A | Arm Label: Medication; Type: N/A; Interventions: N/A
C: Arm Label: Mind-Body Skills Groups; Type: EXPERIMENTAL; Interventions: Behavioral: Mind-Body Skills Groups | Arm Label: Delayed Intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mind-Body Skills Groups; Assigned to Arm(s): Mind-Body Skills Groups
D: Arm Label: Depression Care Management; Type: EXPERIMENTAL; Interventions: Drug: Sertraline | Arm Label: Care as Usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): Depression Care Management

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study SCA104779, an Evaluation of BW430C (Lamotrigine) Versus Placebo in the Prevention of Mood Episodes in Bipolar I Disorder Patients
Brief Summary: This study is planned to objectively assess the efficacy and safety of lamotrigine maintenance therapy after symptoms of mood episode had been stabilised by open-label treatment with lamotrigine alone or in combination with other psychotropic medication in patients with bipolar I disorder.


Options:
A: Intervention Type: BEHAVIORAL; Name: Psychoeduction; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Cognitive-Behavioral Therapy; Assigned to Arm(s): N/A
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: BW430C(lamotrigine); Type: ACTIVE_COMPARATOR; Interventions: Drug: lamotrigine | Intervention Type: DRUG; Name: lamotrigine; Assigned to Arm(s): BW430C(lamotrigine) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Arm 1; Type: OTHER; Interventions: Drug: lamotrigine | Intervention Type: DRUG; Name: lamotrigine; Assigned to Arm(s): Arm 1
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: lamotrigine | Arm Label: lamotrigine; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): lamotrigine | Intervention Type: DRUG; Name: lamotrigine; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2b, Randomized, Double Blind, Placebo Controlled Active Comparator, Multicenter Study To Compare 5 Dose Regimens Of CP- 690,550 And Adalimumab Versus Placebo, Administered For 6 Months In The Treatment Of Subjects With Active Rheumatoid Arthritis
Brief Summary: The purpose of this study is to determine the effectiveness and safety, over 6 months, of 5 doses of CP-690,550 for the treatment of adults with active rheumatoid arthritis. Five out of seven subjects will receive CP-690,550. One out of seven will receive adalimumab (Humira®) and one out of seven will only receive inactive substances (placebo.)


Options:
A: Arm Label: Active 5mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Active 10 mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo Sequence 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo Sequence 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active 5mg | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active 10 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Sequence 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Sequence 2
B: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo, Drug: MTX | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Biological: Infliximab, Drug: MTX | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: MTX; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Infliximab; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: MTX; Assigned to Arm(s): 2
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Adalimumab | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: CP-690-550 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: CP-690-550 | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: CP-690-550 | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 6; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 7; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: CP-690-550; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: CP-690-550; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: CP-690-550; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 5 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 6 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 7
D: Arm Label: Certolizumab pegol (CZP); Type: EXPERIMENTAL; Interventions: Drug: Certolizumab pegol (CZP) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Certolizumab pegol (CZP); Assigned to Arm(s): Certolizumab pegol (CZP) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase IIA Trial of 1% Topical Cidofovir for Treatment of High-Grade Perianal Squamous Intraepithelial Lesions in HIV-Infected Men and Women
Brief Summary: RATIONALE: High-grade squamous intraepithelial lesions of the skin near the anus are caused by the human papillomavirus (HPV). Antiviral drugs,, such as cidofovir, act against viruses and may stop these lesions from becoming cancer.

PURPOSE: This phase II trial is studying the side effects and how well topical cidofovir works in treating HIV-infected patients with high-grade squamous intraepithelial lesions of the skin near the anus.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: V501 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Comparator: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Biological: Human Papillomavirus (HPV) 16 Monovalent | Intervention Type: BIOLOGICAL; Name: V501; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Comparator: Placebo; Assigned to Arm(s): 2 | Intervention Type: BIOLOGICAL; Name: Human Papillomavirus (HPV) 16 Monovalent; Assigned to Arm(s): 3
B: Arm Label: Quadrivalent Human Papillomavirus (HPV) Vaccine; Type: EXPERIMENTAL; Interventions: Biological: Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Matching Placebo | Intervention Type: BIOLOGICAL; Name: Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine; Assigned to Arm(s): Quadrivalent Human Papillomavirus (HPV) Vaccine | Intervention Type: BIOLOGICAL; Name: Matching Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Cidofovir; Type: EXPERIMENTAL; Interventions: Drug: cidofovir, Genetic: DNA methylation analysis, Genetic: gene expression analysis, Genetic: polymerase chain reaction, Procedure: biopsy, Procedure: histopathologic examination | Intervention Type: DRUG; Name: cidofovir; Assigned to Arm(s): Cidofovir | Intervention Type: GENETIC; Name: DNA methylation analysis; Assigned to Arm(s): Cidofovir | Intervention Type: GENETIC; Name: gene expression analysis; Assigned to Arm(s): Cidofovir | Intervention Type: GENETIC; Name: polymerase chain reaction; Assigned to Arm(s): Cidofovir | Intervention Type: PROCEDURE; Name: biopsy; Assigned to Arm(s): Cidofovir | Intervention Type: PROCEDURE; Name: histopathologic examination; Assigned to Arm(s): Cidofovir
D: Intervention Type: PROCEDURE; Name: CO2 laser surgery; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: ultrasonic surgical aspiration; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical and Neuropsychological Validity of Attention-Deficit Hyperactivity Disorder in Adulthood
Brief Summary: This study aims to establish the psychometric properties of the Adult ADHD Quality of Life Scale (AAQoL) and to validate the diagnosis of adult ADHD by ADHD symptoms, other clinical psychiatric symptoms, neuropsychological functioning, social/family/occupational functioning, and intervention effect.


Options:
A: Arm Label: Ritalin LA; Type: EXPERIMENTAL; Interventions: Drug: Ritalin LA (methylphenidate hydrochloride extended release) | Intervention Type: DRUG; Name: Ritalin LA (methylphenidate hydrochloride extended release); Assigned to Arm(s): Ritalin LA
B: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: open label PR OROS methylphenidate | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: double blind PR OROS methylphenidate | Arm Label: 003; Type: PLACEBO_COMPARATOR; Interventions: Drug: double blind placebo | Intervention Type: DRUG; Name: double blind placebo; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: double blind PR OROS methylphenidate; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: open label PR OROS methylphenidate; Assigned to Arm(s): 001
C: N/A
D: Arm Label: Methylphenidate; Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate | Arm Label: Matching Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Matching Placebo | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Methylphenidate | Intervention Type: OTHER; Name: Matching Placebo; Assigned to Arm(s): Matching Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical and Neuropsychological Validity of Attention-Deficit Hyperactivity Disorder in Adulthood
Brief Summary: This study aims to establish the psychometric properties of the Adult ADHD Quality of Life Scale (AAQoL) and to validate the diagnosis of adult ADHD by ADHD symptoms, other clinical psychiatric symptoms, neuropsychological functioning, social/family/occupational functioning, and intervention effect.


Options:
A: N/A
B: Arm Label: Methylphenidate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate (OROS-MPH) | Arm Label: Methylphenidate (Placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: Methylphenidate (OROS-MPH) - Placebo | Intervention Type: DRUG; Name: Methylphenidate (OROS-MPH); Assigned to Arm(s): Methylphenidate | Intervention Type: DRUG; Name: Methylphenidate (OROS-MPH) - Placebo; Assigned to Arm(s): Methylphenidate (Placebo)
C: Arm Label: Midazolam; Type: EXPERIMENTAL; Interventions: Drug: Midazolam | Arm Label: Isotonic saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Isotonic saline | Arm Label: Fentanyl; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fentanyl | Intervention Type: DRUG; Name: Midazolam; Assigned to Arm(s): Midazolam | Intervention Type: DRUG; Name: Fentanyl; Assigned to Arm(s): Fentanyl | Intervention Type: DRUG; Name: Isotonic saline; Assigned to Arm(s): Isotonic saline
D: Arm Label: Medication Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vyvanse, Drug: Methylphenidate | Arm Label: Behavioral Parent Training Arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioral Parent Training | Intervention Type: DRUG; Name: Vyvanse; Assigned to Arm(s): Medication Arm | Intervention Type: BEHAVIORAL; Name: Behavioral Parent Training; Assigned to Arm(s): Behavioral Parent Training Arm | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Medication Arm

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical and Neuropsychological Validity of Attention-Deficit Hyperactivity Disorder in Adulthood
Brief Summary: This study aims to establish the psychometric properties of the Adult ADHD Quality of Life Scale (AAQoL) and to validate the diagnosis of adult ADHD by ADHD symptoms, other clinical psychiatric symptoms, neuropsychological functioning, social/family/occupational functioning, and intervention effect.


Options:
A: Intervention Type: DRUG; Name: methylphenidate hydrochloride extended-release tablets; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: methylphenidate hydrochloride; Assigned to Arm(s): N/A
C: Arm Label: Osmotic-Release Methylphenidate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Osmotic-Release Methylphenidate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Osmotic-Release Methylphenidate; Assigned to Arm(s): Osmotic-Release Methylphenidate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Single Arm, Open Label Study to Assess the Efficacy, Safety, and Tolerability of Once-Monthly Administration of Intravenous C.E.R.A. for the Maintenance of Haemoglobin Levels in Dialysis Patients With Chronic Renal Anaemia
Brief Summary: This single-arm study will assess the efficacy and safety of intravenous (IV) Mircera when administered for the maintenance of hemoglobin (Hb) levels in participants with chronic renal anemia. Individuals currently receiving maintenance treatment with epoetin alfa or darbepoetin alfa will receive monthly injections of Mircera, with the starting dose (120, 200, or 360 micrograms \[mcg\] IV injection) derived from the dose of epoetin alfa or darbepoetin alfa they were receiving in the week preceding study start.


Options:
A: Arm Label: CERA Treatment Once Monthly; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Darbepoetin Alfa Once Biweekly; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin Alfa Once Biweekly | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): CERA Treatment Once Monthly
B: Arm Label: RO0503821 (1x/2 Weeks); Type: EXPERIMENTAL; Interventions: Drug: RO0503821 (1x/2 Weeks) | Arm Label: RO0503821 (1x/4 Weeks); Type: EXPERIMENTAL; Interventions: Drug: RO0503821 (1x/4 Weeks) | Arm Label: Epoetin (1-3x/Weeks); Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin alfa or beta | Intervention Type: DRUG; Name: Epoetin alfa or beta; Assigned to Arm(s): Epoetin (1-3x/Weeks) | Intervention Type: DRUG; Name: RO0503821 (1x/2 Weeks); Assigned to Arm(s): RO0503821 (1x/2 Weeks) | Intervention Type: DRUG; Name: RO0503821 (1x/4 Weeks); Assigned to Arm(s): RO0503821 (1x/4 Weeks)
C: Arm Label: Mircera in Renal Anemia; Type: EXPERIMENTAL; Interventions: Drug: Methoxy polyethylene glycol-epoetin beta | Intervention Type: DRUG; Name: Methoxy polyethylene glycol-epoetin beta; Assigned to Arm(s): Mircera in Renal Anemia
D: Arm Label: Mircera in Renal Anemia; Type: EXPERIMENTAL; Interventions: Drug: Methoxy polyethylene glycol-epoetin beta | Intervention Type: DRUG; Name: Methoxy polyethylene glycol-epoetin beta; Assigned to Arm(s): Mircera in Renal Anemia

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of a Psychoeducative Program for Improving Quality of Life in Fibromyalgic Patients [Study Protocol]
Brief Summary: This research project pretends to demonstrate that a psychoeducative program implemented in the context of PC can produce a significant increase in the quality of life of patients with FM, as well as a decrease in the use of sanitary and social services, compared to usual care.


Options:
A: Arm Label: ACT; Type: EXPERIMENTAL; Interventions: Behavioral: ACT | Arm Label: Physical activity; Type: EXPERIMENTAL; Interventions: Other: Physical activity | Arm Label: Experience based discussion group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: ACT; Assigned to Arm(s): ACT | Intervention Type: OTHER; Name: Physical activity; Assigned to Arm(s): Physical activity
B: Intervention Type: BEHAVIORAL; Name: cognitive-behavioral therapy; Assigned to Arm(s): N/A
C: Arm Label: A Exposure long; Type: EXPERIMENTAL; Interventions: Behavioral: Exposure in vivo | Arm Label: B Exposure short; Type: EXPERIMENTAL; Interventions: Behavioral: Exposure in vivo | Arm Label: C Cognitive behavioural psychotherapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Behavioural Psychotherapy | Intervention Type: BEHAVIORAL; Name: Exposure in vivo; Assigned to Arm(s): A Exposure long, B Exposure short | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioural Psychotherapy; Assigned to Arm(s): C Cognitive behavioural psychotherapy
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Psychoeducative program in fibromyalgic patients | Intervention Type: BEHAVIORAL; Name: Psychoeducative program in fibromyalgic patients; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of a Psychoeducative Program for Improving Quality of Life in Fibromyalgic Patients [Study Protocol]
Brief Summary: This research project pretends to demonstrate that a psychoeducative program implemented in the context of PC can produce a significant increase in the quality of life of patients with FM, as well as a decrease in the use of sanitary and social services, compared to usual care.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Psychoeducative program in fibromyalgic patients | Intervention Type: BEHAVIORAL; Name: Psychoeducative program in fibromyalgic patients; Assigned to Arm(s): 1
B: Arm Label: CBT and milnacipran; Type: EXPERIMENTAL; Interventions: Other: CBT and milnacipran | Arm Label: CBT and placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: CBT with a placebo | Arm Label: Educational with milnacipran; Type: ACTIVE_COMPARATOR; Interventions: Drug: Educational with milnacipran | Intervention Type: OTHER; Name: CBT and milnacipran; Assigned to Arm(s): CBT and milnacipran | Intervention Type: BEHAVIORAL; Name: CBT with a placebo; Assigned to Arm(s): CBT and placebo | Intervention Type: DRUG; Name: Educational with milnacipran; Assigned to Arm(s): Educational with milnacipran
C: Arm Label: Group education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Group education | Arm Label: 8-form Yang-style Tai chi program; Type: EXPERIMENTAL; Interventions: Behavioral: 8-form Yang-style Tai chi | Intervention Type: BEHAVIORAL; Name: 8-form Yang-style Tai chi; Assigned to Arm(s): 8-form Yang-style Tai chi program | Intervention Type: BEHAVIORAL; Name: Group education; Assigned to Arm(s): Group education
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle physical activity (LPA) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Fibromyalgia education | Intervention Type: BEHAVIORAL; Name: Lifestyle physical activity (LPA); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Fibromyalgia education; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Bicalutamide Monotherapy Preserves Bone Mineral Density, Muscle Strength and Has Significant Quality of Life Benefits for Men With Advanced Prostate Cancer
Brief Summary: The aim of this study is to comprehensively monitor the effects of a nonsteroidal antiandrogen in patients requiring hormone manipulation for prostate cancer


Options:
A: Arm Label: Bicalutamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bicalutamide | Intervention Type: DRUG; Name: Bicalutamide; Assigned to Arm(s): Bicalutamide
B: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bicalutamide | Intervention Type: DRUG; Name: Bicalutamide; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A
C: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bicalutamide | Intervention Type: DRUG; Name: Bicalutamide; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Bicalutamide | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Bicalutamide; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pilot Efficacy Trial of a Computer Decision Support System Compared to Usual Care for Depression Treatment in Primary Care
Brief Summary: The purpose of this study was designed to test the feasibility and effectiveness of implementing a Computerized Decision Support System for depression (CDSS-D) during acute care in a primary care setting.


Options:
A: Arm Label: CDSS-D; Type: EXPERIMENTAL; Interventions: Other: Computerized Decision Support System for Depression (CDSS-D) | Arm Label: UC; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care (UC) | Intervention Type: OTHER; Name: Computerized Decision Support System for Depression (CDSS-D); Assigned to Arm(s): CDSS-D | Intervention Type: OTHER; Name: Usual Care (UC); Assigned to Arm(s): UC
B: Intervention Type: OTHER; Name: educational intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: internet-based intervention; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: evaluation of cancer risk factors; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: fecal occult blood test; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: screening colonoscopy; Assigned to Arm(s): N/A
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Osteoporosis Choice Decision Aid | Arm Label: Arm 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Osteoporosis Choice Decision Aid; Assigned to Arm(s): Arm 1
D: Arm Label: White educational video; Type: N/A; Interventions: N/A | Arm Label: African-American educational video; Type: N/A; Interventions: N/A | Arm Label: Usual care; Type: N/A; Interventions: N/A

Answer: A